Enteric-Coated Digestive Enzyme Beads for Stable Low-Dose Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing digestive enzyme formulations, particularly for conditions like exocrine pancreatic insufficiency, face challenges in maintaining stability and accurate dosing, especially for infants and geriatric patients, due to high enzyme content variability and gastric inactivation, leading to potential under or over-dosing issues.
Innovation Solution
A stable, low dosage digestive enzyme composition comprising enterically coated beads with a controlled enzyme content (4-20% by weight) and large carrier particles, packaged in moisture-resistant containers with desiccants, ensuring high uniformity and minimal enzymatic activity loss during storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high enzyme content is used in digestive enzyme formulations, then therapeutic efficacy is improved, but dosing precision and stability deteriorate due to enzyme variability and gastric inactivation
Solution Approach 1:
The formulation segments the enzyme mixture into discrete controlled-release particles or capsules, each containing a precisely measured enzyme content. This segmentation allows for standardized dosing units that maintain therapeutic efficacy while improving dosing precision through controlled release mechanisms that protect against gastric inactivation.
Solution Approach 2:
The invention changes the physical and chemical parameters of the enzyme formulation by using enteric coatings or protective matrices that alter the release profile. This parameter change protects the enzyme from gastric acid inactivation while maintaining controlled release in the intestine, thereby improving both stability and dosing precision without compromising therapeutic efficacy.
2Measurement precision
If enzyme content is reduced for precise dosing in infants and geriatric patients, then dosing precision is improved, but stability and therapeutic efficacy worsen due to enzyme degradation
Solution Approach 1:
The formulation applies protective coatings or encapsulation to the enzyme particles before administration. This preliminary action protects the enzyme from degradation during storage and transit through the gastrointestinal tract, ensuring that even low-dose formulations for infants and geriatric patients maintain their stability and therapeutic efficacy.
Solution Approach 2:
The invention uses composite materials combining the enzyme with protective carriers, enteric coatings, or stabilizing matrices. This composite structure protects the enzyme from degradation while enabling precise dosing, as the composite formulation maintains enzyme stability throughout the gastrointestinal tract.
3Stability of the object's composition
If enteric coating is applied to protect enzymes from gastric inactivation, then enzyme stability is improved, but manufacturing complexity increases
Solution Approach 1:
The enteric coating is applied locally to specific regions of the enzyme particles or capsules rather than requiring complex system-wide modifications. This localized approach provides the necessary protection against gastric inactivation while simplifying the manufacturing process compared to more complex delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains enzymatic activity for extended periods, allowing precise dosing and effective treatment of digestive enzyme deficiencies, particularly in infants and newborns, with minimal enzyme loss and improved stability.
Implementation Method 1
challenges in maintaining stability and accurate dosing, especially for infants and geriatric patients, due to high enzyme content variability and gastric inactivation
Implementation Method 2
packaged in moisture-resistant containers with desiccants, ensuring high uniformity and minimal enzymatic activity loss during storage
Implementation Method 3
packaged in moisture-resistant containers with desiccants, ensuring high uniformity and minimal enzymatic activity loss during storage
Data Source
AI summary
The present invention is directed to a pharmaceutical composition or dosage form having a stable, low (diluted) digestive enzyme content comprising at least one digestive enzyme and at least one carrier, or a dosage form thereof. The invention is also directed to a process of preparation of the composition or the dosage form. In addition the invention is directed to the treatment and prevention of disorders or conditions associated with a digestive enzyme deficiency in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable amount of the composition having a stable low digestive enzyme content or dosage form thereof.